Update on the Medical Management of Crohn's Disease

Overview

Journal Curr Gastroenterol Rep

Specialty Gastroenterology

Date 2015 Sep 14

PMID 26363802

Citations 3

Authors

Parakkal Deepak

David H Bruining

Affiliations

Soon will be listed here.

Abstract

The medical management of Crohn's disease is a rapidly evolving field with expanding therapeutic drug options and treatment strategies. In addition to corticosteroids, immunomodulators, and anti-tumor necrosis (anti-TNF) agents, a new anti-adhesion medication (vedolizumab) has been approved. Individualized patient-based dosing of immunomodulators and biologic agents is now possible with therapeutic drug monitoring (TDM). There is a changing paradigm in treatment goals to achieve deeper remission identified by composite clinical and endoscopic endpoints. More aggressive treatment strategies in the postoperative setting have been proposed due to emerging data on medication efficacy in this setting. Management algorithms that stratify CD patients into risk groups to balance treatment benefit against adverse events and costs are being developed to translate research into clinical practice. This review provides an update on these new developments for practicing gastroenterologists.

Citing Articles

Altered Gut Microbial Fermentation and Colonization with in Renal Transplant Recipients.

Knobbe T, Douwes R, Kremer D, Swarte J, Eisenga M, Gomes-Neto A J Clin Med. 2020; 9(2).

PMID: 32075113 PMC: 7073595. DOI: 10.3390/jcm9020518.

Frontiers in Drug Research and Development for Inflammatory Bowel Disease.

Curro D, Pugliese D, Armuzzi A Front Pharmacol. 2017; 8:400.

PMID: 28690543 PMC: 5481609. DOI: 10.3389/fphar.2017.00400.

Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.

Deepak P, Loftus Jr E Drug Des Devel Ther. 2016; 10:3685-3698.

PMID: 27956825 PMC: 5113936. DOI: 10.2147/DDDT.S102141.

References

Aguas M, Bastida G, Cerrillo E, Beltran B, Iborra M, Sanchez-Montes C . Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients. World J Gastroenterol. 2012; 18(32):4391-8. PMC: 3436056. DOI: 10.3748/wjg.v18.i32.4391. View

Allez M, Karmiris K, Louis E, Van Assche G, Ben-Horin S, Klein A . Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis. 2010; 4(4):355-66. DOI: 10.1016/j.crohns.2010.04.004. View

Narula N, Peyrin-Biroulet L, Colombel J . Combination therapy with methotrexate in inflammatory bowel disease: time to COMMIT?. Gastroenterology. 2014; 146(3):608-11. DOI: 10.1053/j.gastro.2014.01.040. View

Papamichael K, Archavlis E, Lariou C, Mantzaris G . Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study. J Crohns Colitis. 2012; 6(9):924-31. DOI: 10.1016/j.crohns.2012.02.012. View

Bryant R, Sandborn W, Travis S . Introducing vedolizumab to clinical practice: who, when, and how?. J Crohns Colitis. 2015; 9(4):356-66. DOI: 10.1093/ecco-jcc/jjv033. View

Sandborn W, Hanauer S, Van Assche G, Panes J, Wilson S, Petersson J . Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis. 2014; 8(9):927-35. DOI: 10.1016/j.crohns.2014.02.021. View

Steenholdt C, Molazahi A, Ainsworth M, Brynskov J, Thomsen O, Seidelin J . Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol. 2012; 47(5):518-27. DOI: 10.3109/00365521.2012.660541. View

Ford A, Kane S, Khan K, Achkar J, Talley N, Marshall J . Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106(4):617-29. DOI: 10.1038/ajg.2011.71. View

Panaccione R, Colombel J, Sandborn W, DHaens G, Zhou Q, Pollack P . Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther. 2013; 38(10):1236-47. PMC: 4670480. DOI: 10.1111/apt.12499. View

10.

Ungar B, Chowers Y, Yavzori M, Picard O, Fudim E, Har-Noy O . The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut. 2013; 63(8):1258-64. DOI: 10.1136/gutjnl-2013-305259. View

11.

Roblin X, Marotte H, Rinaudo M, Del Tedesco E, Moreau A, Phelip J . Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2013; 12(1):80-84.e2. DOI: 10.1016/j.cgh.2013.07.010. View

12.

Cosnes J, Gower-Rousseau C, Seksik P, Cortot A . Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011; 140(6):1785-94. DOI: 10.1053/j.gastro.2011.01.055. View

13.

Brandse J, Peters C, Gecse K, Eshuis E, Jansen J, Tuynman H . Effects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory Crohn's disease. Inflamm Bowel Dis. 2014; 20(2):251-8. DOI: 10.1097/01.MIB.0000438248.14218.1d. View

14.

Chatu S, Subramanian V, Saxena S, Pollok R . The role of thiopurines in reducing the need for surgical resection in Crohn's disease: a systematic review and meta-analysis. Am J Gastroenterol. 2013; 109(1):23-34. DOI: 10.1038/ajg.2013.402. View

15.

Hashash J, Regueiro M . The evolving management of postoperative Crohn's disease. Expert Rev Gastroenterol Hepatol. 2012; 6(5):637-48. DOI: 10.1586/egh.12.45. View

16.

Colombel J, Rutgeerts P, Sandborn W, Yang M, Camez A, Pollack P . Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2013; 12(3):414-22.e5. DOI: 10.1016/j.cgh.2013.06.019. View

17.

Schoepfer A, Bortolotti M, Pittet V, Mottet C, Gonvers J, Reich O . The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn's disease. Aliment Pharmacol Ther. 2014; 40(8):930-7. DOI: 10.1111/apt.12929. View

18.

Yoshida K, Fukunaga K, Ikeuchi H, Kamikozuru K, Hida N, Ohda Y . Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflamm Bowel Dis. 2011; 18(9):1617-23. DOI: 10.1002/ibd.21928. View

19.

Singh S, Garg S, Pardi D, Wang Z, Murad M, Loftus Jr E . Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis. Mayo Clin Proc. 2014; 89(12):1621-35. DOI: 10.1016/j.mayocp.2014.08.019. View

20.

Eshuis E, Peters C, van Bodegraven A, Bartelsman J, Bemelman W, Fockens P . Ten years of infliximab for Crohn's disease: outcome in 469 patients from 2 tertiary referral centers. Inflamm Bowel Dis. 2013; 19(8):1622-30. DOI: 10.1097/MIB.0b013e318281f4c4. View